![Fouzia Laghrissi-Thodes](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Fouzia Laghrissi-Thodes
Direttore/Membro del Consiglio presso MINERVA NEUROSCIENCES, INC.
Patrimonio netto: - $ in data 30/06/2024
Profilo
Fouzia Laghrissi-Thodes is currently the Chief Executive Officer & Director at DalCor Pharmaceuticals Canada, Inc. She is also an Independent Director at Minerva Neurosciences, Inc., Smart Immune SAS, and Cellaïon SA. Previously, Dr. Laghrissi-Thodes served as the Chief Executive Officer at ZS Pharma, Inc. She also held positions as a Director at Nuro Corp.
and as the VP-Cardiovascular & Metabolism Therapy at AstraZeneca PLC.
Dr. Laghrissi-Thodes obtained a doctorate degree from Université François-Rabelais de Tours.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
31/03/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Posizioni attive di Fouzia Laghrissi-Thodes
Società | Posizione | Inizio |
---|---|---|
MINERVA NEUROSCIENCES, INC. | Direttore/Membro del Consiglio | 18/05/2015 |
DalCor Pharmaceuticals Canada, Inc.
![]() DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | Amministratore Delegato | 03/04/2018 |
Smart Immune SAS
![]() Smart Immune SAS BiotechnologyHealth Technology Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017. | Direttore/Membro del Consiglio | - |
Cellaïon SA
![]() Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Fouzia Laghrissi-Thodes
Società | Posizione | Fine |
---|---|---|
ZS PHARMA INC | Amministratore Delegato | - |
Nuro Corp.
![]() Nuro Corp. Packaged SoftwareTechnology Services Nuro Corp. provides neurological communication software. The company was founded by Francois Gand, Abhinav Kumar and Pascal Gand and is headquartered in Waterloo, Canada. | Direttore/Membro del Consiglio | - |
ASTRAZENECA PLC | Corporate Officer/Principal | - |
Formazione di Fouzia Laghrissi-Thodes
Université François-Rabelais de Tours | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
MINERVA NEUROSCIENCES, INC. | Health Technology |
ASTRAZENECA PLC | Health Technology |
Aziende private | 5 |
---|---|
DalCor Pharmaceuticals Canada, Inc.
![]() DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | Health Technology |
ZS Pharma, Inc.
![]() ZS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA. | Health Technology |
Smart Immune SAS
![]() Smart Immune SAS BiotechnologyHealth Technology Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017. | Health Technology |
Cellaïon SA
![]() Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Health Technology |
Nuro Corp.
![]() Nuro Corp. Packaged SoftwareTechnology Services Nuro Corp. provides neurological communication software. The company was founded by Francois Gand, Abhinav Kumar and Pascal Gand and is headquartered in Waterloo, Canada. | Technology Services |
- Borsa valori
- Insiders
- Fouzia Laghrissi-Thodes